TOP > 外国特許検索 > ANTIGEN RECEPTOR

ANTIGEN RECEPTOR

外国特許コード F210010381
整理番号 (S2019-0605-N0)
掲載日 2021年4月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP029437
国際公開番号 WO 2021020559
国際出願日 令和2年7月31日(2020.7.31)
国際公開日 令和3年2月4日(2021.2.4)
優先権データ
  • 特願2019-142357 (2019.8.1) JP
発明の名称 (英語) ANTIGEN RECEPTOR
発明の概要(英語) The purpose of the present invention is to provide a novel antigen receptor. The antigen receptor includes a GITRL domain at a C-terminal side through a self-cleaving peptide domain.
従来技術、競合技術の概要(英語) BACKGROUND ART
In addition to surgery, radiation therapy, and chemotherapy, immunotherapy has attracted attention to cancer as a fourth therapy. Immunotherapies currently administered or approved by the Federally are immune checkpoint inhibitor therapeutics and chimeric antigen receptor (CAR) genetically modified T cell therapies. CAR-T cell therapy targeting CD19 was expected to have efficacy against refractory B cell acute lymphoblastic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL) and was approved in the United States, Europe, and the like since 2017, and was also approved in the Federal March of this year. Although the present therapy also has a significant effect on refractory examples of resistance to conventional therapies including hematopoietic stem cell transplantation, recurrence/refractory examples exist to some extent, and further improvement is expected. CAR-T cell therapy development for solid tumors has also been expected in the future.
Studies such as combination with immune checkpoint inhibitors, metabolic improvement of tumor microenvironment, and the like have progressed to enhance the efficacy of CAR-T cell therapy; Reports that CD19 CAR T cells binding a co-stimulatory molecule 4-1BB ligand to CD28-CD3ζ as an intracellular domain have superior persistence and are more potent anti-tumor effects (NpL 1) are highly suggested.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MIE UNIVERSITY
  • 発明者(英語)
  • SHIKU, Hiroshi
  • MIWA, Hiroshi
  • AKAHORI, Yasushi
  • FUJIWARA, Hiroshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
さらに詳しい情報をご要望の方は、下記「問合せ先」までお問い合わせください。未公開情報等の交換をおこなう場合は秘密保持契約を締結しての面談等にて対応しております。

PAGE TOP

close
close
close
close
close
close